Virtonomy GmbH
Accelerating and de-risking medical device development with digital patient twins: Virtonomy enables medical device developers to perform development and testing in a virtual environment, thereby accelerating development, reducing risks, expenses, and regulatory burden. Our end-to-end digital twin and simulation solution is based on an ever-expanding database of real clinical data to reflect anatomical variability, demographic diversity and pathological conditions.
Founded: 2019 Headquarters:Paul-Heyse-Straße 6 ,80336
Company
Products
Uploads
By: Virtonomy GmbH
Accelerate clinical trials with digital patient twins, ensure their success, reduce costs and time
Virtonomy empowers medical device developers with v-Patients, a virtual testing and development platform enabling developers to validate their device design on digital patient twins. By leveraging our comprehensive digital twin and simulation technology, built on a constantly growing database of real clinical data (CT/MRI scans of real patients), we help developers account for anatomical differences, demographic diversity, and various medical conditions. This approach accelerates product development, minimizes risks and costs, and simplifies regulatory compliance, transforming the way medical devices are brought to market.
Virtonomy’s virtual trial platform supports the full product life cycle of medical device development, from concept phase to regulatory reporting and clinical practice.
Thousands of Virtual Patients:
Advanced Statistical Shape Models:
Advanced Anatomical Simulations:
Regulatory Services & Consultation:
The FDA and European Commission show strong support for virtual patients and simulation.
"FDA’s Office of Science and Engineering Laboratories (OSEL) has committed significant resources for transforming computational modeling from a valuable scientific tool to a valuable regulatory tool because of its potential for significant cost-savings in evaluating medical devices, simulating performance under scenarios that may not be possible with human use or that could more effectively be evaluated with simulation." (Source)
More useful links:
FDA’s support on computational modeling
FDA: Diverse racial and ethnic groups for clinical trials